More Videos
|
CNBC'S MOST SHARED
- Unemployed? Bored? Make Money Playing Beer Pong
- Social Networking's 'Naked' Truth
- WPP's Sir Martin Sorrell on the Ad Recession
- The Highest Grossing (Inflation Adjusted) Movies of All Time
- Merrill's McCann Seen as UBS Wealth Frontrunner
- Geek Squad V. Gizmodo
- Warren Buffett's Top Three Investment Rules for the Average American
- Why You Should Watch Fund Flows
- Roginsky: No More Mr. Nice Guy
- Eric Schmidt on Government Scrutiny and Economic Recovery
- Market 360: The Week's Best & Worst
- Geek Squad V. Gizmodo
- Brandt: Google Chrome OS in the Post-PC Age
- Other People Are Weirder Than We Are
- Bank Failures: Is The Nightmare Over? (Video)
- California Here I Go? No.
- Roginsky: No More Mr. Nice Guy
- Commercial Conundrum
- Stimulus Will Kick in Later this Year: President Obama
- Lender CIT Group Hires Premier Bankruptcy Adviser
- Government Selling Bank Stakes for Too Cheap: Panel
- Buffett's Top 3 Investment Rules for Average Americans
- Market Insider: Earnings Loom in the Week Ahead
- Bulls Get Summertime Blues, But It's Hot Fun for Bears
- As Banks Fail, Strong Institutions Become More Visible
- GM IPO in Second Quarter 2010 at the Earliest: CFO
- Merrill's McCann Seen as UBS Wealth Frontrunner
RSS FEED
Text Size 
 |
Chitose Suzuki / AP Boston Scientific Corp. |
Not too long ago, some had written off the potential for significant growth to resume in sales of the little wire mesh tubes that are painted with special drugs to help keep arteries from reclogging. The devices were plagued by safety concerns regarding blood clots forming several months or years after they were put in.
There are now four players in the space and Weinstein is telling clients that the latest entrant, the Xience stent from Abbott[ABT
Loading...
()
], is quickly emerging as the dominant product. Boston Scientific [BSX
Loading...
()
]sells the exact same stent, but under the brand name Promus. Weinstein says that Xience/Promus are already approaching 50 percent market share. "The speed of the shift is fascinating to watch, as cardiologists who just a few months ago were telling us that they would initially use Xience in only a quarter of their procedures are now apparently making it their lead product," he writes.
Medtronic [MDT
Loading...
()
]won approval earlier this year of its drug-coated stent Endeavor. And BSX and Johnson & Johnson [JNJ
Loading...
()
]sell the older products Taxus and Cypher, respectively.
Studies show Xience/Promus work better and may be safer than the other stents and doctors apparently think the new products are easier to insert than the older ones.
Weinstein says, "Boston's (Scientific) marketing of Promus...has turned out to be much more aggressive than expected. The result has been higher Promus uptake, higher Xience uptake, and a rapid drop-off for the existing products."
But Weinstein points out that BSX could be a victim of its own success because it buys the new stents from ABT and then slaps the Promus name on them. "Boston's challenge is that it may not have enough Promus to continue to grow its share within the market. Under the Abbott agreement," he writes, "Boston (Scientific) must forecast and pre-order its supply for each six month period with 3 months of the supply fixed and 3 months variable. Boston can increase its order monthly, but each month there are caps on how much it can raise its order." Interesting.
A lot of disclosures: Someone at JPM is a Director of ABT. A Director of JPM is also a Director of JNJ. JPM has done and wants to do more investment banking for ABT, MDT, JNJ and BSX. And part of JPM makes a market in MDT options. Some readers wonder what's up with the disclosures. CNBC editorial policy requires us to include them in our coverage. You'll also see them in graphics when analysts and money managers appear on CNBC. They were mandated by the SEC to be added to the fine print at the end of research notes following the analysis scandal earlier this decade (i.e. Jack Grubman) to give investors a clearer view of potential conflicts.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes